We analyzed incidence of BM in NSCLC patients with different serum IL6 levels, and results showed the group with higher IL6 levels had a higher risk of brain metastasis (35% vs. 17%, P = 0.012). Here, IL6 is linked to non-small cell lung carcinoma.